[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Michel Doepke [@doepke_michel](/creator/twitter/doepke_michel) on x 4931 followers Created: 2024-02-14 12:02:01 UTC $BMY $TPTX U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors. $LLY $LOXO $RHHBY  XXX engagements  **Related Topics** [$rhhby](/topic/$rhhby) [$loxo](/topic/$loxo) [$lly](/topic/$lly) [$tptx](/topic/$tptx) [$bmy](/topic/$bmy) [stocks healthcare](/topic/stocks-healthcare) [eli lilly](/topic/eli-lilly) [Post Link](https://x.com/doepke_michel/status/1757736954576204191)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Michel Doepke @doepke_michel on x 4931 followers
Created: 2024-02-14 12:02:01 UTC
$BMY $TPTX U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors. $LLY $LOXO $RHHBY
XXX engagements
Related Topics $rhhby $loxo $lly $tptx $bmy stocks healthcare eli lilly
/post/tweet::1757736954576204191